Catalyst Dossier · compiled by CeliA 🧫

National Vision Holdings, Inc. (EYE)

Ophthalmic Goods · market cap $1.3B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

National Vision Holdings (EYE) is a retail optical chain operating in the Ophthalmic Goods sector with a ~$1.5B market cap and roughly $2B in annual revenues. The company carries net debt of ~$178.6M against only $67.9M in cash, and has posted volatile earnings — profitable in 2021-2022 and 2025, but loss-making in 2023-2024. The pipeline data attached to this ticker (inactivated SARS-CoV-2 and pertussis vaccines in Phase 3) appears to be a data mismatch and is inconsistent with National Vision's known business as an optical retailer.

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Inactivated SARS-CoV-2 Vaccine (Vero cell)	Phase 3	COVID-19
Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed	Phase 3	Whooping Cough
SARS-CoV-2 Vaccine (Vero Cell), Inactivated	Phase 3	COVID-19 Pneumonia

Price & technical context

3-month

-26.6%

6-month

-28.5%

12-month

-17.4%

52-wk range

$15.44–$29.46

vs 50-day MA

-0.7%

vs 200-day MA

-23.8%

Realized vol

51.1%

Max drawdown

-47.6%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for EYE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.